|
#17
14.10.2016, 18:19
|
|||
|
|||
|
Ïîñëåäíèå íàøè àíàëèçû êðîâè
Îò 05.10.16: Hb 157 ã/ë Er 5,49 10*12/ë Tr 321 10*9/ë Le 10.4 10*9/ë Ñ/ÿ 64% Ýîç 0,6% Ëèìô 25,4 % Ìîí 10% Ñîý 3 ìì/÷ Íà÷. ñâ. 3 ìèí, êîíåö ñâ.4 ìèí.30ñ Âðåìÿ êðîâ. 1 ìèí. Îò 11.10.16 Hb 151 ã/ë Er 5,2 10*12/ë Tr 386 10*9/ë Le 8,5 10*9/ë Ñ/ÿ 44% Ýîç 2,2% Ëèìô 43% Ìîí 10% Ñîý 3 ìì/÷ ×òî íàì äåëàòü ñ ýðèòðîöèòàìè? Êàêèå äîïîëíèòåëüíûå àíàëèçû ñäàòü? 
|
|
#18
14.10.2016, 18:29
|
||||
|
||||
|
Öèòàòà:
|
|
#19
09.11.2016, 19:45
|
|||
|
|||
|
Çäðàâñòâóéòå! Îáñëåäóåìñÿ. Íàøëè ïîâûøåííûé ýðèòðîïîýòèí â 2 ðàçà, ïîäñêàæèòå ÷òî äåëàòü
ÎÀÊ: Ãåìîãëàáèí 142 Ëåéêàöèòû 4,29 Ýðèòðîöèòû 5,03 Ãåìàòîêðèò 40,9 MCV 81,3 MCH 28,3 MCHC 34,7 RDW-CV 12,5 Òðîìáîöèòû 373 MPV 8,80 Ëèìôîöèòû 1,53*10^9/ë Ìîíîöèòû 0,48*10^9/ë Íåéòðîôèëû 2,11*10^9/ë Ýîçèíîôèëû 0,15*10^9/ë Áàçîôèëû 0,02 Ëèìôîöèòû 35,75% Ìîíîöèòû 11,2% Íåéòðîôèëû 49,1% Ýîçèíîôèëû 3,5% Áàçîôèëû 0,5% Ñîý 2 Ôåððèòèí 19,6 (6,00-320,00) Æåëåçî 20,8 (9,00-21,5) Ýðèòðîïîýòèí 72,09 (8,00-30,00)
|
|
#20
09.11.2016, 19:54
|
||||
|
||||
|
îáðàòèòüñÿ ê î÷íîìó ñïåöèàëèñòó è èñêàòü ïðè÷èíû åðèòðîöèòîçà íà ôîíå ïîâûøåííîãî åðèòðîïîåòèíà, âîò ñïèñîê ïðîáëåì/äèàãíîçîâ ó âçðîñëûõ - íàâåðíîå ó äåòåé òîæå àêòóàëåí
EPO mediated-hypoxia driven • Chronic lung Diseases • Chronic Carbon monoxide exposure (smoking) • Right to Left Cardiac shunts • High Altitude • Hypoventilation syndromes • Sleep apneas • Respiratory center dysfunctions • Renal artery stenosis • High affinity Hb • 2, 3-DPG deficiency Pathologic EPO production tumors producing excessive erythropoietin • Hepatocellular carcinoma • Renal cell Cancer • Cerebellar hemangioblastoma Non malignant conditions • Uterine leiomyoma • Renal cysts • Hydronephrosis • Adrenal tumors • Atrial myxoma
|
|
#22
09.11.2016, 20:04
|
||||
|
||||
|
ïî÷å÷íûå êèñòû äàæå ìàëåíüêèõ ðàçìåðîâ ó äåòåé ìîãóò ïîâûøàòü åðèòðîïîåòèí â êðîâè äî 40-50 è âûçûâàòü åðèòðîöèòîç, îïåðàòèâíîå óäàëåíèå âñ¸ íîðìàëèçóåò:
J Pediatr Surg. 2002 Oct;37(10):1491-2. Polycythemia secondary to multiloculated renal cyst in a child. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
|
|
#23
21.02.2017, 12:11
|
|||
|
|||
|
Çäðàâñòâóéòå! Ñåé÷àñ ðåáåíêó 12 ëåò. Ðàçáèðàåìñÿ ñ ïðîáëåìîé ãëàç. Ïðåäñòàèò îïåðàöèÿ íà ãëàç.
Ñäàëè ÎÀÊ 11.02.17 Ãåìîãëàáèí 146 Òðîìáîöèòû 354 (íîðìà ëàá. 154-442) Ýðèòðàöèòû 5,03 (íîðìà ëàá. 3.9-5.1) Ëåéêîöèòû 6.03*10^9 ë (íîðì ëàá 4,5-13) Íåéòðàôèëû 49.5% (íîðì ëàá 43-60) Ýîçèíîôèëû 13.8% Áàçîôèëû 0.7% Ëèìôîöèòû 24.9% Ìîíîöèòû 11.1% ÑÎÝ 3 Ñêîðîñòü îñåäàíèÿ ýðèòðîöèòîâ 3 ìì/÷ (íîðìà 1-10) Ðàññ÷èòàííàÿ øèðèíà êðèâîé ðàñïðåäåëåíèÿ ýðèòðîöèòîâ 12,8% (íîðìà 11.6-14) Ñðåäíèé îáúåì ýðèòðîöèòîâ 83.9 ôë (76-94) Ñðåäíåå ñîäåðæàíèå ãåìîãëîáèíà â ýðèòðîöèòå 29 ïã (26-32) Êîíöåíòðàöèÿ ãåìîãëîáèíà â ýðèòðîöèòàõ 34,6 ã/äë (íîðìà 32-37) Íàçíà÷èëè Íåìëçîë 400 1 ðàç â äåíü íà 3 äíÿ. Ïðîïèëè 12. 13. 14 ôåâðàëÿ. Ïîâòîðèëè ÎÀÊ 19.02.17 Ãåìîãëàáèí 143 Òðîìáîöèòû 358 (íîðìà ëàá. 154-442) Ýðèòðàöèòû 4.91 (íîðìà ëàá. 3.9-5.1) Ëåéêîöèòû 7.4*10^9 ë (íîðì ëàá 4,5-13) Íåéòðàôèëû 30% (íîðì ëàá 43-60) Ýîçèíîôèëû 18% Áàçîôèëû 0.0% Ëèìôîöèòû 41% Ìîíîöèòû 11% ÑÎÝ 3 Ñêîðîñòü îñåäàíèÿ ýðèòðîöèòîâ 3 ìì/÷ (íîðìà 1-10) Ðàññ÷èòàííàÿ øèðèíà êðèâîé ðàñïðåäåëåíèÿ ýðèòðîöèòîâ 12,7% (íîðìà 11.6-14) Ñðåäíèé îáúåì ýðèòðîöèòîâ 84.9 ôë (76-94) Ñðåäíåå ñîäåðæàíèå ãåìîãëîáèíà â ýðèòðîöèòå 29.1 ïã (26-32) Êîíöåíòðàöèÿ ãåìîãëîáèíà â ýðèòðîöèòàõ 34.3 ã/äë (íîðìà 32-37) Ïðîòðîìáèí ïî Êâèêó 64.8% (íîðìà 70-100%) Ïðîòðîìáèíîâîå âðåìÿ 14.9 ñ (10.2-13) Ïðîòðîìáèíîâûé èíäåêñ 1.22 (0.9-1.3) ÌÍÎ 1.27 Ôèáðèíîãåí 2.43 (1.5-4) ×òî äåëàòü è êóäà áåæàòü? Îïåðàöèÿ íà ñëåäóþùåé íåäåëå.
|
Ëèíåéíûé âèä
